|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ҩ�ﳬ����Ӧ�ۺ��� |
|
����� |
|
���� |
|
�����6��,�� |
|
���� |
| ��������������� | |
|
ʯƽ�� |
|
� |
|
����Ⱥ |
|
���� |
| PubMed | |
|
Article by SHI Ping-rong |
|
Article by LI Kai |
|
Article by DUAN Yi-qun |
|
Article by ZHOU Xiao-yong |
ҩ�ﳬ����Ӧ�ۺ����������Ƽ����Ƶ��о���չ
ʯƽ��, �, ����Ⱥ, ��С��
�人�е�һҽԺƤ���� 430022
ҩ�ﳬ����Ӧ�ۺ�����һ�־��������������֢ҩ�Ŀǰ��Ϊ,��һ�����Ŵ�������,�����ҩ����Դ�л����ⶾ���ܵ�ȱ�����䲡��֮һ,�������-6��Ⱦ�ټ���Ҳ�����˴˲��ķ�����ҩ�Ｐ�����ټ������������߹�����Ӧ������֯����Ҫ��CD8+ϸ������T�ܰ�ϸ����ɡ�����䲡������ı�,����Ч�������Dz��ü����������������Ʒ���
Drug-induced Hypersensitivity Syndrome
Department of Dermatology, the First Hospital of Wuhan, Wuhan 430022, China
Department of Dermatology, the First Hospital of Wuhan, Wuhan 430022, China
Drug-induced hypersensitivity syndrome (DIHS) is a severe drug eruption with characteristic symptoms. The etiology of DIHS is complex and the mechanism of it has not been fully elucidated. The pathogenic factors include the defect in the process of detoxifying reactive drug metabolites, which is related to a specific genetic background, and human herpes virus 6 (HHV-6) reactivation. The drug and virus reactivation destroy tissues by an immune allergic reaction. And the destruction is primarily caused by CD8+ cytotoxic T lymphocytes. Aiming at the pathological changes, systemic glucocorticoids (GS) with intravenous immunoglobulin (IVIG) are the most effective therapy.
[2] Enomoto M,Ochi M,Teramae K,et al.Codeine phosphate-induced hypersensitivity syndrome.Ann Pharmacother,2004,38:799-802.
[3] Mitani N,Aihara M,Yamakawa Y,et al.Drug-induced hypersensitivity syndrome due to cyanamide associated with multiple reactivation of human herpesviruses.J Med Virol,2005,75:430-434.
[4] Tohyama M,Yahata Y,Yasukawa M,et al.Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6.Arch Dermatol,1998,134:1113-1117.
[5] Suzuki Y,Inagi R,Aono T,et al.Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome.Arch Dermatol,1998,134:1108-1112.
[6] Aihara Y,Ito SI,Kobayashi Y,et al.Carbamazepine-induced hypersensitivity syndrome associated with transient hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction.Br J Dermatol,2003,149:165-169.
[7] Hashimoto K,Yasukawa M,Tohyama M.Human herpesvirus 6 and drug allergy.Curr Opin Allergy Clin Immunol,2003,3:255-260.
[8] Kano Y,Inaoka M,Sakuma K,et al.Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome.Toxicology,2005,209:165-167.
[9] Ohtani T,Hiroi A,Sakurane M,et al.Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.Br J Dermatol,2003,148:1035-1039.
[10] Martin AM,Nolan D,Gaudieri S,et al.Pharmacogenetics of antiretroviral therapy:genetic variation of response and toxicity.Pharmacogenomics,2004,5:643-655.
[11] Mallal S,Nolan D,Witt C,et al.Association between presence of HLA-B*5701,HLA-DR7,and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.Lancet,2002,359:727-732.
[12] Martin AM,Nolan D,Gaudieri S,et al.Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.Proc Natl Acad Sci U S A,2004,101:4180-4185.
[13] Hung SI,Chung WH,Liou LB,et al.HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc Natl Acad Sci U S A,2005,102:4134-4139.
[14] Sullivan JR,Shear NH.The drug hypersensitivity syndrome:what is the pathogenesis? Arch Dermatol,2001,137:357-364.
[15] Naisbitt DJ,Pirmohamed M,Park BK.Immunopharmacology of hypersensitivity reactions to drugs.Curr Allergy Asthma Rep,2003,3:22-29.
[16] Posadas SJ,Padial A,Torres MJ,et al.Delayed reactions to drugs show levels of perforin,granzyme B,and Fas-L to be related to disease severity.J Allergy Clin Immunol,2002,109:155-161.
[17] Yawalkar N,Pichler WJ.Immunohistology of drug-induced exanthema:clues to pathogenesis.Curr Opin Allergy Clin Immunol,2001,1:299-303.
[18] Shepherd GM.Hypersensitivity reactions to drugs:evaluation and management.Mt Sinai J Med,2003,70:113-125.
[19] Kakimoto M,Hasegawa A,Fujita S,et al.Phenotypic and functional alterations of dendritic cells induced by human herpesvirus 6 infection.J Virol,2002,76:10338-10345.
[20] Zou P,Isegawa Y,Nakano K,et al.Human herpesvirus 6 open reading frame U83 encodes a functional chemokine.J Virol,1999,73:5926-5933.
[21] Hasegawa A,Yasukawa M,Sakai I,et al.Transcriptional down-regulation of CXC chemokine receptor 4 induced by impaired association of transcription regulator YY1 with c-Myc in human herpesvirus 6-infected cells.J Immunol,2001,166:1125-1131.
[22] Redondo P,de Felipe I,de la Pena A,et al.Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis.Treatment with N-acetylcysteine.Br J Dermatol,1997,136:645-646.
[23] �؝�����.DIHS��SJS/TEN�Τ褦����֢ˎ����ί��Ȇ��}�c.ҽѧ�Τ���,2003,205:965-971.
[24] Scheuerman O,Nofech-Moses Y,Rachmel A,et al.Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin.Pediatrics,2001,107:E14.
[25] Prins C,Kerdel FA,Padilla RS,et al.Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins:multicenter retrospective analysis of 48 consecutive cases.Arch Dermatol,2003,139:26-32.